a Department of Clinical Nutrition, School of Nutrition and Food Science, Student Research Committee, Isfahan University of Medical Sciences , Isfahan , Iran.
b National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences , Tehran , Iran.
Crit Rev Food Sci Nutr. 2019;59(15):2494-2505. doi: 10.1080/10408398.2018.1458021. Epub 2018 Apr 20.
: We systematically reviewed available randomized clinical trials (RCTs) to elucidate the overall effects of synbiotic supplementation in patients with nonalcoholic fatty liver disease (NAFLD). : PubMed, Scopus, ISI Web of science and Google Scholar were searched up to December, 2017. All RCTs using synbiotic supplements to treat NAFLD included in this systematic review and meta-analysis. Mean Difference (MD) was pooled using a random-effects model. : Eleven eligible databases from seven RCTs were identified for the present meta-analysis. Our results showed that synbiotic supplementation can decrease body weight, fasting blood sugar, insulin, low density lipoprotein cholesterol, total cholesterol, triglyceride, high-sensitivity C-reactive protein, tumor necrosis factor alpha, alanine transaminase and aspartate transaminase levels among patients with NAFLD. In contrast, synbiotic did not have favorable effects on body mass index (BMI), waist circumference, homeostasis model assessment for insulin resistance (HOMA-IR), and high density lipoprotein cholesterol (HDL) levels compared with the placebo group. : The current study revealed that synbiotic supplementation has favorable effect on inflammatory factors, liver enzymes and some anthropometric indices, lipid profiles and glucose homeostasis parameters in patients with NAFLD.
我们系统地回顾了现有的随机临床试验（RCTs），以阐明益生菌联合治疗非酒精性脂肪性肝病（NAFLD）患者的总体效果。
检索了 PubMed、Scopus、ISI Web of Science 和 Google Scholar，截至 2017 年 12 月。本系统评价和荟萃分析纳入了所有使用益生菌联合治疗 NAFLD 的 RCT。使用随机效应模型汇总均数差（MD）。
从 7 项 RCT 中确定了 11 项符合条件的数据库进行本次荟萃分析。我们的结果表明，益生菌联合治疗可以降低 NAFLD 患者的体重、空腹血糖、胰岛素、低密度脂蛋白胆固醇、总胆固醇、甘油三酯、高敏 C 反应蛋白、肿瘤坏死因子-α、丙氨酸转氨酶和天冬氨酸转氨酶水平。相比之下，与安慰剂组相比，益生菌对体重指数（BMI）、腰围、胰岛素抵抗评估的稳态模型（HOMA-IR）和高密度脂蛋白胆固醇（HDL）水平没有有利影响。
目前的研究表明，益生菌联合治疗对 NAFLD 患者的炎症因子、肝酶和一些人体测量指标、血脂谱和血糖稳态参数有良好的影响。
